Literature DB >> 34350612

The Impact of Granulocyte Colony Stimulating Factor on Patients Receiving Chimeric Antigen Receptor T-Cell Therapy.

Jason N Barreto1, Radhika Bansal2, Matthew A Hathcock2, Corina J Doleski1, Justin R Hayne2, Tuan A Truong3, Adrienne N Nedved1, Stephen M Ansell2, N Nora Bennani2, Jonas Paludo2, Jose C Villasboas2, Yi Lin2, Patrick B Johnston2.   

Abstract

Preliminary results of this work were presented as a poster at the 62nd American Society of Hematology Annual Meeting and Exposition, December 5-7, 2020, and as an oral presentation at the 2021 TCT Meetings of ASTCT & CIBMTR digital experience, February 8-12, 2021 This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2021        PMID： 34350612     DOI： 10.1002/ajh.26313

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  3 in total

Review 1.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

Review 2.  CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.

Authors:  Alankrita Taneja; Tania Jain
Journal:  EJHaem       Date:  2021-11-21

3.  The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.

Authors:  Kai Rejeski; Ariel Perez; Gloria Iacoboni; Olaf Penack; Veit Bücklein; Liv Jentzsch; Dimitrios Mougiakakos; Grace Johnson; Brian Arciola; Cecilia Carpio; Viktoria Blumenberg; Eva Hoster; Lars Bullinger; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Pere Barba; Michael D Jain; Marion Subklewe
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.